Vizamyl® is a radioactive diagnostic agent used for positron emission tomography (PET) imaging of the brain in order to estimate the β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Pathologically increased amyloid deposition in the gray matter in a patient with suspected Alzheimer’s disease.
The following indication is reimbursed by the health insurance:
Senior Attending Physician, Department of Nuclear Medicine
Deputy Clinic Director, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Diagnostic Neuroradiologist, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Senior Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Neuroradiologist, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.
Simply assign your patient via registration form.
Medical information hotline: 08.00-18.00 o’clock: +41 44 255 15 02